Non-vitamin K oral anticoagulants (NOAC) have been shown to be safe and effective
alternatives to warfarin for stroke prevention in patients with nonvalvular AF (NVAF). There
are yet limited real life data on outcomes following elective cardioversion in AF patients
treated with NOACs. The aim of this study is to investigate the complications and the use of
NOACs in AF patients undergoing cardioversion.